Studies of the mechanistic details of the pH-dependent association of botulinum neurotoxin with membranes. Mushrush DJ, Koteiche HA, Sammons MA, Link AJ, McHaourab HS, Lacy DB (2011) J Biol Chem 286: 27011-8 Re: Treatment Outcomes and Resource Use of Patients With Neurogenic Detrusor Overactivity Receiving Botulinum Toxin A (BOTOX) Therapy in Germany. Penson DF (2011) J Urol 185: 1383-4 Women Undergoing Third Line Overactive Bladder Treatment Demonstrate Elevated Thermal Temporal Summation. Reynolds WS, Kowalik C, Cohn J, Kaufman M, Wein A, Dmochowski R, Bruehl S (2018) J Urol 200: 856-861 Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, Penson DF (2011) World J Urol 29: 51-7 The impact of frailty on treatment for overactive bladder in older adults. Suskind AM, Kowalik C, Quanstrom K, Boscardin J, Zhao S, Reynolds WS, Mishra K, Finlayson E (2019) Neurourol Urodyn 38: 1915-1923 Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. Lacy DB, Stevens RC (1997) Protein Expr Purif 11: 195-200
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.